Surgery Partners closes $797M Idaho Falls sale as earnings profile resets

Surgery Partners is moving away from owning broader acute-care assets and toward a purer short-stay surgical platform, using portfolio actions to improve leverage and cash conversion. The Idaho Falls sale was already announced in July, so the closing itself is confirmation rather than a fresh strategic surprise.

The transaction delivers meaningful liquidity and completes the portfolio reset. Surgery Partners received $797 million in gross proceeds and $587 million in net cash proceeds at closing. The sale values the facilities at approximately $1.15 billion and represents roughly 7x trailing adjusted EBITDA, giving the company cash to reduce leverage while exiting a business outside its desired pure-play profile.

The reported earnings base gets smaller, but the remaining business is presented as higher quality. Management is removing Idaho Falls from the rest of 2026, which lowers the headline revenue and EBITDA outlook; the pro forma figures show the ongoing company investors will actually own. The company says the divestiture should be accretive to annual adjusted earnings growth, mainly through lower leverage, better free-cash-flow conversion and a more focused operating model.

The read is mixed because the economics are constructive but the event was largely expected. The cash proceeds and completed deleveraging step advance the strategy, but there is no major new information about the direction of the business: the sale, its approximate valuation and the planned pure-play repositioning were already disclosed. The main new information is that closing occurred and the final proceeds were slightly above the previously announced consideration.

Bottom line: This is a meaningful balance-sheet and focus improvement, not a surprise catalyst. SGRY now has a cleaner short-stay surgery story, but with a smaller reported revenue and EBITDA footprint after the divestiture.